Here are some answers to commonly asked questions about YORVIPATH
1.What is YORVIPATH indicated for?
YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.1
YORVIPATH was not studied for acute post-surgical hypoparathyroidism. YORVIPATH’s titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of ≥7.8 mg/dL using calcium and active vitamin D treatment.
Learn more about YORVIPATH efficacy here.
2.How does YORVIPATH work, and how does it affect PTH and calcium levels?
The active PTH from YORVIPATH acts similarly to endogenous PTH. Endogenous PTH maintains extracellular calcium and phosphate homeostasis by increasing serum calcium and decreasing serum phosphate through multiple mechanisms. YORVIPATH exerts its effects through the primary receptor for PTH, parathyroid hormone 1 receptor (PTH1R), located throughout the body and highly expressed on osteoblasts, osteocytes, renal tubular cells, and in other tissues.1
View more information about the mechanism of action of YORVIPATH here.
3.What is the most common side effect associated with YORVIPATH?
Injection site reaction was the most common adverse reaction, occurring in 39% of YORVIPATH-treated patients compared to 5% of placebo-treated patients. No drug-related discontinuations were reported in the 26-week blinded period of the clinical trial.1,2 Learn more about YORVIPATH safety here.
4.How is YORVIPATH taken?
YORVIPATH is administered subcutaneously in the front of the thigh or abdomen. The injection site should be rotated daily. YORVIPATH should be administered at the same time every day.1 View more dosing and administration information here.
5.How is YORVIPATH titrated?
The goal of titrating YORVIPATH is to maintain normal serum calcium levels while achieving independence from conventional therapy. Patients should be titrated off active vitamin D before titrating down calcium. The recommended starting dose of YORVIPATH is 18 mcg, and dose adjustments should be made in 3-mcg increments or decrements.1 See more detailed titration information here.
6.What happens if a YORVIPATH dose is missed?
If it has been less than 12 hours from the previous dose, YORVIPATH should be taken as soon as possible. If it has been more than 12 hours, skip YORVIPATH and take the next dose as scheduled.1 View more detailed dosing information here.
7.How often does serum calcium need to be measured?
Measure serum calcium 7 to 10 days after the first YORVIPATH dose and after any dose change in YORVIPATH, active vitamin D, or calcium, and monitor for clinical signs and symptoms of hypocalcemia or hypercalcemia. Once the YORVIPATH maintenance dosage is achieved, measure serum calcium levels at a minimum of every 4 to 6 weeks or as indicated for symptoms of hypocalcemia or hypercalcemia.1 View more detailed dosing and titration information here.
8.How do I enroll/start my patient on YORVIPATH?
To start your patient on YORVIPATH, the Enrollment Form must be completed. By submitting this form, you are initiating Ascendis Signature Access Program® (A·S·A·P) enrollment, which provides patients with support throughout treatment. A Patient Consent Form will also need to be submitted so they can begin receiving personalized support.
9.What support is available for patients starting YORVIPATH?
There are helpful resources and support information available for patients starting YORVIPATH, including the What to Expect With YORVIPATH brochure. Explore more resources here.
10.What types of support and resources related to YORVIPATH are available for office staff and healthcare professionals?
A variety of resources are available to support office staff and healthcare professionals, including the HCP Start Guide. Explore more resources here.
11.Is support available to help with YORVIPATH cost?
Yes, the Ascendis Signature Access Program can help eligible patients seek financial assistance when needed. The Co-Pay Program is also available for commercially insured and eligible patients. Learn more about financial assistance here.
